<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994912</url>
  </required_header>
  <id_info>
    <org_study_id>EI-001-101</org_study_id>
    <nct_id>NCT04994912</nct_id>
  </id_info>
  <brief_title>First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers</brief_title>
  <official_title>Title of Study: A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elixiron Immunotherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elixiron Immunotherapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess&#xD;
      the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability of single ascending intravenous (IV) doses of EI-001 in&#xD;
      healthy volunteers&#xD;
&#xD;
      To assess the pharmacokinetics (PK) of single ascending IV doses of EI-001 in healthy&#xD;
      volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>to assess blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>to assess heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>to assess respiratory rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess time to maximum observed drug concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>to assess AUC from time zero to the last measurable concentration (AUC0-t)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>EI-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EI-001</intervention_name>
    <description>EI-001 IV infusion</description>
    <arm_group_label>EI-001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female 18 to â‰¤ 55 years old at the time of consent.&#xD;
&#xD;
          2. Healthy on the basis of physical examination, medical history, vital signs, laboratory&#xD;
             values and 12-lead ECG performed at Screening. The participant may be included only if&#xD;
             the investigator judges any abnormalities or deviations from normal to be not&#xD;
             clinically significant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior or ongoing medical conditions, medical history, physical findings, or laboratory&#xD;
             abnormality that, in the Investigator's (or delegate's) opinion, may require treatment&#xD;
             or render the participant unlikely to fully complete the study, or any condition that&#xD;
             presents undue risk from the IP or procedures or interfere with study assessments.&#xD;
&#xD;
          2. Have received any IP within 30 days or 5 half-lives prior to Screening (4 months if&#xD;
             the previous drug was a new chemical entity), whichever is longer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

